Resultados de la búsqueda

Domínguez F. Etiological diagnosis of myocarditis: an unresolved issue? Rev Esp Cardiol (2025) S1885-5857:00236-1

Valverde-Gómez M, De La Higuera-Romero L, Pérez-Barbeito M, García-Hernández S, Cárdenas-Reyes I, Ochoa JP. TTN cardiomyopathy: expanding clinical relevance beyond the A-band. Rev Esp Cardiol (2025) S1885-5857:00195-1

Cabrera-Romero E, Serrao-Faria LA, Mora-Ayestarán N, Peiró-Aventín B, Espinoza A, de Castro D, Cobo-Marcos M, Domínguez F, González-López E, Garcia-Pavia P. Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy. Amyloid (2025) 32:87-89

Suhr OB, Grogan M, Silva AMD, Karam C, Garcia-Pavia P, Drachman B, Zago W, Tripuraneni R, Kinney GG. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. Amyloid (2025) 32:14-21

Davis BJ, Volk H, Nguyen O, Kamna D, Chen H, Barriales-Villa R, Garcia-Pavia P, Olivotto I, Owens AT, Coats CJ, Abraham TP, Solomon SD, Maron MS, Masri A. Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy J Am Heart Assoc (2025) 14:e038758
Link to the full text in Repisalud

Filamin C Registry Consortium; Gigli M, Stolfo D, Barbati G, Graw S, Chen SN, Merlo M, Medo K, Gregorio C, Dal Ferro M, Paldino A, Perotto M, Peter van Tintelen J, Te Riele ASJM, Baas AF, Wilde AM, Amin AS, Houweling AC, Elliott P, Cannie D, Michels M, Schoonvelde SAC, Prasad S, Tayal PU, Yazdani M, Morris-Rosendahl D, Garcia-Pavia P, Cabrera-Romero E, Bauce B, Pilichou K, Fatkin D, Johnson R, Judge DP, Foil KL, Heymans S, Verdonschot JAJ, Stroeks SLVM, Lakdawala NK, Anisha P, O'Neill M, Shoemaker MB, Roden DM, Calkins H, James CA, Murray B, Parikh VN, Ashley EA, Reuter C, Imazio M, Canepa M, Ameri P, Song J, Sinagra G, Taylor MRG, Mestroni L. Arrhythmic Risk Stratification of Carriers of Filamin C Truncating Variants. JAMA Cardiol (2025) 10:359-369

Garcia-Pavia P, Kristen AV, Drachman B, Carlsson M, Amass L, Maurer MS; THAOS investigators. Understanding how long people with transthyretin amyloid cardiomyopathy (ATTR-CM) live when they take tafamidis as part of their regular healthcare: a plain language summary. Future Cardiol (2025) 21:433-445

Jurcut R, Barriales-Villa R, Biagini E, Garcia-Pavia P, Olivotto I, Protonotarios A, Arbustini E, Mogensen J, Elliott P, Arbelo E, Pablo Kaski J; Members of the Task Force for the 2023 ESC Guidelines for the management of cardiomyopathies. Key priorities for the implementation of the 2023 ESC Guidelines for the Management of Cardiomyopathies in low resource settings. Eur Heart J Qual Care Clin Outcomes (2025) Mar 31 [Epub ahead of print]

Mora-Ayestarán N, Gil-Llopis C, González-Maniega C, Piovano MV, Águila-Gordo D, Briceño A, González-Vioque E, Domínguez F, González-López E, Garcia-Pavia P. Impact of Genetic Testing Family Screening in Hereditary Transthyretin Amyloidosis. JACC CardioOncol (2025) 7:763-766

Crespo-Leiro MG, Hanna M, Damy T, Delgado D, Ebede B, Marino V, Wang R, Maurer MS, Garcia-Pavia P, Drachman BM. arly Access to Tafamidis for Patients With Transthyretin Amyloid Cardiomyopathy. JACC Adv (2025) 4:102122